CN112839712A - 用于减少或治疗发炎的组合物和方法 - Google Patents

用于减少或治疗发炎的组合物和方法 Download PDF

Info

Publication number
CN112839712A
CN112839712A CN201980054580.3A CN201980054580A CN112839712A CN 112839712 A CN112839712 A CN 112839712A CN 201980054580 A CN201980054580 A CN 201980054580A CN 112839712 A CN112839712 A CN 112839712A
Authority
CN
China
Prior art keywords
amino acid
composition
acid entity
entity
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980054580.3A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·哈米尔
瑞弗·亚非恩
李中伟
哈利·路易特哈特
西蒙·青山
斯维特拉娜·马鲁基安
纳丁·道尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axcella Health Inc
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of CN112839712A publication Critical patent/CN112839712A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201980054580.3A 2018-06-20 2019-06-19 用于减少或治疗发炎的组合物和方法 Pending CN112839712A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862687724P 2018-06-20 2018-06-20
US62/687,724 2018-06-20
US201862758249P 2018-11-09 2018-11-09
US62/758,249 2018-11-09
US201962794165P 2019-01-18 2019-01-18
US62/794,165 2019-01-18
PCT/US2019/038055 WO2019246310A1 (en) 2018-06-20 2019-06-19 Compositions and methods for the reduction or treatment of inflammation

Publications (1)

Publication Number Publication Date
CN112839712A true CN112839712A (zh) 2021-05-25

Family

ID=67253998

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980054580.3A Pending CN112839712A (zh) 2018-06-20 2019-06-19 用于减少或治疗发炎的组合物和方法

Country Status (6)

Country Link
US (1) US20210260010A1 (https=)
EP (1) EP3810276A1 (https=)
JP (1) JP2021529736A (https=)
CN (1) CN112839712A (https=)
MA (1) MA52961A (https=)
WO (1) WO2019246310A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
JP2021529735A (ja) 2018-06-20 2021-11-04 アクセラ・ヘルス・インコーポレイテッドＡｘｃｅｌｌａ Ｈｅａｌｔｈ Ｉｎｃ． アミノ酸組成物の製造方法
US20210379118A1 (en) * 2018-10-19 2021-12-09 Regenics As Use of egg cellular extract for wound healing
WO2023009444A1 (en) * 2021-07-26 2023-02-02 Axcella Health Inc. Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19
US11622949B1 (en) 2022-08-04 2023-04-11 Gad M. Gilad Agmatine compositions for treatment of osteoarthritis
US12285541B2 (en) 2023-01-26 2025-04-29 Insignia Pharmaceuticals, Llc Pharmaceutical compositions for treating osteoarthritis
CN116549428B (zh) * 2023-06-20 2025-05-16 郑州大学 4-羟基异亮氨酸的新用途
WO2025155743A1 (en) * 2024-01-16 2025-07-24 The Johns Hopkins University Chemokine ligand 18 (ccl18) for diagnosis and treatment of inflammatory lung disease

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101049500A (zh) * 2007-02-15 2007-10-10 北京苏里曼医药科技有限公司 一种氨基酸组合物
US20080108684A1 (en) * 2005-07-01 2008-05-08 Ajinomoto Co., Inc. Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor
US20110081329A1 (en) * 2006-06-07 2011-04-07 Daniel S. Smith Amino acid compositions
KR20170051079A (ko) * 2015-11-02 2017-05-11 (주)모아캠 아미노산 및 해양 심층수 추출 미네랄을 유효성분으로 함유하는 화장료 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2863809A1 (en) * 2012-02-06 2013-08-15 Ajinomoto Co., Inc. Prophylactic or therapeutic agent for idiopathic inflammatory myopathies
JOP20190147A1 (ar) * 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080108684A1 (en) * 2005-07-01 2008-05-08 Ajinomoto Co., Inc. Therapeutic agent for inflammatory bowel disease and tnf-alfa production inhibitor
US20110081329A1 (en) * 2006-06-07 2011-04-07 Daniel S. Smith Amino acid compositions
CN101049500A (zh) * 2007-02-15 2007-10-10 北京苏里曼医药科技有限公司 一种氨基酸组合物
KR20170051079A (ko) * 2015-11-02 2017-05-11 (주)모아캠 아미노산 및 해양 심층수 추출 미네랄을 유효성분으로 함유하는 화장료 조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KEVIN J MULHALL等: "Comparison of different anti-inflammatory agents in suppressiong the monocyte response to orthopedic paticles", 《ORTHOPEDICS》, vol. 26, no. 12, pages 1219 - 1223 *

Also Published As

Publication number Publication date
US20210260010A1 (en) 2021-08-26
EP3810276A1 (en) 2021-04-28
WO2019246310A1 (en) 2019-12-26
MA52961A (fr) 2021-04-28
JP2021529736A (ja) 2021-11-04

Similar Documents

Publication Publication Date Title
CN112839712A (zh) 用于减少或治疗发炎的组合物和方法
US20240041810A1 (en) Amino acid compositions and methods for the treatment of liver diseases
US20240238232A1 (en) Compositions and methods for the reduction or treatment of insulin resistance and metabolic conditions
US20210154238A1 (en) Extracellular vesicles with enhanced potency
JP2018517782A (ja) 相乗的飲料組成物
CN116234542A (zh) 代谢物的免疫效应
US20210275480A1 (en) Compositions and methods for the reduction or treatment of fibrosis
CN117398372A (zh) Ostarine在抑制NLRP3炎症小体活化中的应用
Han et al. Urea functions as a risk signal driving astrocyte-mediated neuroinflammation following stroke
US20230000808A1 (en) Compositions and methods excluding or with reduced glutamine for the treatment of hemoglobinopathies and thalassemias
Herencia et al. Cardiotrophin-1 decreases liver apoptosis through calpastatin induction
KR20240139551A (ko) 허혈-재관류 손상의 예방 또는 치료용 약학 조성물
US20130059913A1 (en) Composition for amelioration of hypoalbuminemia
HK40121784A (zh) 用於预防和/或治疗肠病的包含氨基酸的组合物
JP2015531341A (ja) グルタチオンを含有する免疫増強剤
WO2022109465A1 (en) Antiviral therapeutic compounds and compositions for use in treatment of coronavirus and influenza virus
KR20180038225A (ko) 디아민 유도체를 포함하는 뇌졸중, 신경 세포 손상, 파킨슨병 또는 루게릭병의 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210525